CHICAGO, IL – Sheridan Capital Partners, a Chicago-based lower middle-market private equity firm, announced today that it has completed a leveraged buyout of Diamondback Drugs (“Diamondback”).
Diamondback, headquartered in Scottsdale, AZ, is a leading national veterinary specialty compounding pharmacy, serving veterinary clinics and hospitals, zoos and aquariums, and consumers across all 50 states. Diamondback offers customized compounded pharmaceutical products, in multiple dosage forms, to thousands of customers annually. The Company specializes in formulations for oncology, heart disease, diabetes, Cushing's disease, exotic diseases and conditions, infections, and neurological disorders.
“Diamondback Drugs offers an incredible opportunity to back an experienced management team dedicated to delivering the best possible quality products to pet owners across the country. Thanks to the Company’s world-class facility, deep clinical knowledge, and industry leading compounded pharmaceutical offering, Sheridan believes Diamondback is well positioned to continue its growth in the animal health space,” said Jonathan Lewis, Partner of Sheridan Capital Partners. “We are excited to partner with Diamondback’s founders, Michael Blaire and Rory Albert, to support the Company’s ongoing strategic initiatives.”
Michael Blaire, Co-Founder and Chief Executive Officer of Diamondback Drugs, said, “Sheridan Capital Partners is the ideal partner for Diamondback. Their strategic and operational resources offer us a unique opportunity to focus on growth initiatives while maintaining our industry leading standard of care for our patients.” Mike Allietta, Partner of Sheridan Capital Partners, said, “Diamondback’s extensive product catalog is unmatched in the industry today. We believe Diamondback is perfectly positioned to achieve extraordinary growth while maintaining their unwavering commitment to key stakeholders.”
The transaction was led by Lewis and Allietta of Sheridan Capital Partners.
About Sheridan Capital Partners
Sheridan Capital Partners, headquartered in Chicago, Illinois, focuses on making private equity investments in leveraged buyouts, recapitalizations and large minority financings of growing lower middle market growth companies with enterprise values between $20 million and $150 million within the healthcare and consumer sectors.
Jonathan Lewis, Partner